YIDU TECH (02158) experienced a significant surge in its stock price during the late trading session on Friday. The company's shares soared by 5.50%, demonstrating strong market interest in the AI healthcare firm.

The rally appears to be driven by YIDU TECH's recent participation in the prestigious "T20+ Conference" held in Suzhou. At the event, the company showcased its cutting-edge intelligent clinical research integrated solutions, highlighting the potential of AI in revolutionizing the drug development process. YIDU TECH's presentation focused on demonstrating replicable pathways for enhancing clinical research efficiency through AI technology, which seems to have resonated well with investors.

YIDU TECH's strong market position, serving over 350 domestic and international pharmaceutical companies and boasting experience from 686 clinical trial projects, likely contributed to investor confidence. The company's Vice President, Liu Ying, emphasized that their AI-powered solutions can accelerate key drug development stages by over 30%, potentially leading to significant cost reductions and faster product launches. This technological edge and its implications for the pharmaceutical industry appear to be the primary factors behind the stock's impressive performance.